Kidney Transplantation
Conditions
Brief summary
Patients planning to have kidney transplantation who are sensitized to their donors have high levels of donor specific alloantibodies. High levels of donor specific antibodies put kidney transplant recipients at risk for rejection very early after transplant. This study is trying to determine if the drug bortezomib (Velcade ™) can reduce donor specific alloantibodies to a level that permits kidney transplantation without a high risk for rejection.
Detailed description
The study is designed to assess the impact of in vivo treatment of bortezomib on anti-human leukocyte antigen (HLA) production by normal antibody secreting cells (ASC) in sensitized renal allograft candidates. The design involves treatment of subjects with bortezomib using one of three dosing regimens (4 doses, 16 doses or 32 doses of bortezomib). Using novel assays, anti-HLA production is determined by measuring the bone marrow derived ASC at baseline (prior to therapy) and after treatment (at day 14, 3 days after the last bortezomib dose). Paired data are used with patients serving as their own controls. Finally, the safety of bortezomib is evaluated by monitoring total serum antibody levels and the incidence of side effects (primarily neuropathy) at 1 month, the final follow-up point.
Interventions
DRUGBortezomib
Velcade given in four-dose cycles intravenously (through a vein).
Sponsors
Millennium Pharmaceuticals, Inc.
Mayo Clinic
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Voluntary written informed consent before performance of any study-related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the subject at any time without prejudice to future medical care. * Female subject is post-menopausal, surgically sterilized, or she and/or sexual partner are willing to use an acceptable method of birth control (i.e., a hormonal contraceptive, intra-uterine device, diaphragm with spermicide, condom with spermicide, or abstinence) for the duration of the study. * Male subject agrees to use an acceptable method for contraception for the duration of the study. * Renal transplant candidates who otherwise meet our acceptance criteria. * Evidence of alloantibody in their serum (panel reactive antibody \>20% and specificities determined by single antigen flow bead assay). * Sensitized patients with no living donors or have donor-specific antibody levels too high to undergo successful transplantation using our current protocols (T or B cell crossmatch channel shift \>500).
Exclusion criteria
* Patient has a platelet count of \<30 x 10\^9/L within 14 days before enrollment. * Patient has an absolute neutrophil count (ANC) of \<1.0 x 10\^9/L within 14 days before enrollment. * Patient has \>Grade 2 peripheral neuropathy within 14 days before enrollment. * Myocardial infarction within 6 months prior to enrollment or has New York Heart Association (NYHA) Class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities. Prior to study entry, any electrocardiogram (ECG) abnormality at Screening has to be documented by the investigator as not medically relevant. * Patient has hypersensitivity to bortezomib, boron or mannitol. * Female subject is pregnant or breast-feeding. Confirmation that the subject is not pregnant must be established by a negative serum B-human chorionic gonadotropin (B-hCG) pregnancy test result obtained during screening. Pregnancy testing is not required for post-menopausal or surgically sterilized women. * Patient has received other investigational drugs within14 days before enrollment. * Serious medical or psychiatric illness likely to interfere with participation in this clinical study. * Diagnosed or treated for malignancy within 5 years of enrollment, with the exception of complete resection of basal cell carcinoma or squamous cell carcinoma of the skin, an in situ malignancy, or low-risk prostate cancer after curative therapy. * Contraindication to kidney transplantation-active infection, comorbid medical conditions, etc.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Response to Bortezomib Monotherapy | 6 months | Response to treatment with Bortezomib (BTZ) alone was defined as a reduction in serum Donor Specific Alloantibody (DSA) levels following treatment. DSA levels were measured prior to treatment and after treatment. A good response occurred if all DSA were reduced. A partial response when a reduction was observed in at least one DSA, but not all DSA. No response occurred when no reduction of any DSA was attained. |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| 4 Dose Group 4 doses of bortezomib (1.3mg/m\^2 of body surface area)
Bortezomib: Velcade given in four-dose cycles intravenously (through a vein). | 3 |
| 16 Dose Group 16 doses of bortezomib (1.3mg/m\^2 of body surface area)
Bortezomib: Velcade given in four-dose cycles intravenously (through a vein). | 5 |
| 32 Dose Group 32 doses of bortezomib (1.3mg/m\^2 of body surface area)
Bortezomib: Velcade given in four-dose cycles intravenously (through a vein). | 10 |
| Total | 18 |
Baseline characteristics
| Characteristic | 4 Dose Group | 16 Dose Group | 32 Dose Group | Total |
|---|---|---|---|---|
| Age, Continuous | 35.3 years STANDARD_DEVIATION 3.5 | 40.4 years STANDARD_DEVIATION 11.4 | 39.5 years STANDARD_DEVIATION 6.6 | 39.1 years STANDARD_DEVIATION 7.6 |
| Region of Enrollment United States | 3 participants | 5 participants | 10 participants | 18 participants |
| Sex: Female, Male Female | 2 Participants | 5 Participants | 7 Participants | 14 Participants |
| Sex: Female, Male Male | 1 Participants | 0 Participants | 3 Participants | 4 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk |
|---|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — | — / — |
| other Total, other adverse events | 3 / 3 | 5 / 5 | 10 / 10 |
| serious Total, serious adverse events | 0 / 3 | 0 / 5 | 0 / 10 |
Outcome results
Primary
Response to Bortezomib Monotherapy
Response to treatment with Bortezomib (BTZ) alone was defined as a reduction in serum Donor Specific Alloantibody (DSA) levels following treatment. DSA levels were measured prior to treatment and after treatment. A good response occurred if all DSA were reduced. A partial response when a reduction was observed in at least one DSA, but not all DSA. No response occurred when no reduction of any DSA was attained.
Time frame: 6 months
Population: In the 32 dose group, one patient received a kidney transplant with a B-cell flow cytometric crossmatch channel shift of less than 300 after dose 20 and was transplanted with a positive crossmatch donor. This patient was then excluded from further DSA analysis.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| 4 Dose Group | Response to Bortezomib Monotherapy | No Response | 2 participants |
| 4 Dose Group | Response to Bortezomib Monotherapy | Good Response | 0 participants |
| 4 Dose Group | Response to Bortezomib Monotherapy | Partial Response | 1 participants |
| 16 Dose Group | Response to Bortezomib Monotherapy | No Response | 4 participants |
| 16 Dose Group | Response to Bortezomib Monotherapy | Good Response | 0 participants |
| 16 Dose Group | Response to Bortezomib Monotherapy | Partial Response | 1 participants |
| 32 Dose Group | Response to Bortezomib Monotherapy | No Response | 3 participants |
| 32 Dose Group | Response to Bortezomib Monotherapy | Good Response | 0 participants |
| 32 Dose Group | Response to Bortezomib Monotherapy | Partial Response | 6 participants |